LIVIVO - The Search Portal for Life Sciences

zur deutschen Oberfläche wechseln
Advanced search

Search results

Result 1 - 10 of total 1061

Search options

  1. Article: CAR T-cell therapy against B-cell maturation antigen in multiple myeloma.

    Cohen, Adam D

    Clinical advances in hematology & oncology : H&O

    2019  Volume 16, Issue 12, Page(s) 804–806

    MeSH term(s) B-Cell Maturation Antigen/antagonists & inhibitors ; B-Cell Maturation Antigen/immunology ; Clinical Trials as Topic ; Humans ; Immunotherapy, Adoptive/adverse effects ; Immunotherapy, Adoptive/methods ; Multiple Myeloma/immunology ; Multiple Myeloma/therapy ; Prognosis ; Receptors, Antigen, T-Cell/genetics ; Receptors, Antigen, T-Cell/metabolism ; Receptors, Chimeric Antigen/genetics ; Receptors, Chimeric Antigen/metabolism ; T-Lymphocytes/immunology ; T-Lymphocytes/metabolism ; Treatment Outcome
    Chemical Substances B-Cell Maturation Antigen ; Receptors, Antigen, T-Cell ; Receptors, Chimeric Antigen
    Language English
    Publishing date 2019-03-07
    Publishing country United States
    Document type Interview
    ZDB-ID 2271951-9
    ISSN 1543-0790
    ISSN 1543-0790
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

    In stock of ZB MED Cologne/Königswinter

    Zs.A 6505: Show issues Location:
    Je nach Verfügbarkeit (siehe Angabe bei Bestand)
    bis Jg. 2021: Bestellungen von Artikeln über das Online-Bestellformular
    ab Jg. 2022: Lesesaal (EG)

    Order via subito

    This service is chargeable due to the Delivery terms set by subito. Orders including an article and supplementary material will be classified as separate orders. In these cases, fees will be demanded for each order.

  2. Article ; Online: Myeloma: next generation immunotherapy.

    Cohen, Adam D

    Hematology. American Society of Hematology. Education Program

    2019  Volume 2019, Issue 1, Page(s) 266–272

    Abstract: ... CD38, CD46, CD48, FcRH5, and G protein-coupled receptor, class C group 5 member D) are moving forward ...

    Abstract The course of multiple myeloma (MM) from initial diagnosis to a relapsed/refractory state is characterized by acquisition of drug resistance as well as progressive immunologic dysfunction. Despite this, however, a number of novel therapies that work in part or solely via immune stimulation are in development for MM, with promising early clinical results. Several new whole-cell or multiepitope vaccine approaches are demonstrating immunologic efficacy in smoldering MM or as posttherapy consolidation, with trials ongoing to see whether this translates into delayed progression or elimination of minimal residual disease. Programmed death-1 (PD-1)/programmed death ligand-1 (PD-L1) inhibition in combination with immunomodulatory drugs demonstrated excessive toxicity in randomized trials; however, antibodies targeting PD-1/PD-L1 and other checkpoint molecules continue to be explored in combination with tumor-targeted antibodies and other T cell-directed therapies. B-cell maturation antigen (BCMA) has emerged as the next big antigen target, with multiple BCMA-specific antibody-drug conjugates (ADCs) and T cell-directed bispecific antibodies/bispecific therapeutic engagers (BiTEs) entering the clinic. In initial trials, the ADC GSK2857916 and the BiTE AMG 420 have demonstrated high response rates in relapsed/refractory patients, with depth and durability of responses that may end up rivaling chimeric antigen receptor T-cell therapies. These agents have unique toxicities that require close monitoring, but they are moving forward in larger registration studies and in combination with standard MM agents. Additional ADCs and bispecific antibodies targeting BCMA and other surface antigens (eg, CD38, CD46, CD48, FcRH5, and G protein-coupled receptor, class C group 5 member D) are moving forward in phase 1 trials and may provide even more options for MM patients.
    MeSH term(s) Aged ; Antibodies, Bispecific/therapeutic use ; Cancer Vaccines/immunology ; Clinical Trials as Topic ; Female ; Humans ; Immunotherapy ; Multiple Myeloma/immunology ; Multiple Myeloma/therapy
    Chemical Substances Antibodies, Bispecific ; Cancer Vaccines
    Language English
    Publishing date 2019-12-06
    Publishing country United States
    Document type Case Reports ; Journal Article ; Review
    ZDB-ID 2084287-9
    ISSN 1520-4383 ; 1520-4391
    ISSN (online) 1520-4383
    ISSN 1520-4391
    DOI 10.1182/hematology.2019000068
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

    Order via subito

    This service is chargeable due to the Delivery terms set by subito. Orders including an article and supplementary material will be classified as separate orders. In these cases, fees will be demanded for each order.

  3. Article ; Online: Options at the time of relapse after anti-BCMA therapy.

    Razzo, Beatrice / Garfall, Alfred L / Cohen, Adam D

    Hematology. American Society of Hematology. Education Program

    2023  Volume 2023, Issue 1, Page(s) 450–458

    Abstract: ... member D and Fc receptor-homolog 5) become available. Going forward, ongoing prospective studies, large ...

    Abstract B-cell maturation antigen (BCMA)-directed therapies, including antibody-drug conjugates, bispecific antibodies (BsAbs), and chimeric antigen receptor T cells (CARTs), have shown remarkable efficacy in patients with late-line myeloma with prior exposure to immunomodulatory agents, proteasome inhibitors, and anti-CD38 antibodies. However, optimal sequencing of these agents remains to be determined, and management of these patients once they relapse has become a new unmet need. Fortunately, there are multiple options with demonstrated activity after anti-BCMA therapy, including a different BCMA-directed therapy, non-BCMA-directed CARTs and BsAbs, novel non-T-cell-engaging drugs, and standard triplet/quadruplet regimens or salvage stem cell transplant. Factors to consider when choosing a next therapy after anti-BCMA therapy include patient characteristics and preferences, prior therapies and toxicities, disease biology, timing from last anti-BCMA therapy, and, in the future, BCMA expression and immune profiling. While current data are limited to retrospective studies and small prospective cohorts, the serial use of T-cell-engaging therapies looks particularly promising, especially as BCMA-directed therapies move up earlier in the myeloma treatment course and additional CARTs and BsAbs against alternative targets (eg, G protein-coupled receptor, family C, group 5, member D and Fc receptor-homolog 5) become available. Going forward, ongoing prospective studies, large real-world data sets, and better tools to interrogate antigen expression and immune cell fitness hopefully will provide further insight into how to best individualize therapy for this difficult-to-treat population.
    MeSH term(s) Humans ; B-Cell Maturation Antigen ; Chronic Disease ; Immunotherapy, Adoptive ; Multiple Myeloma/therapy ; Neoplasm Recurrence, Local ; Prospective Studies ; Retrospective Studies ; Recurrence
    Chemical Substances B-Cell Maturation Antigen
    Language English
    Publishing date 2023-12-09
    Publishing country United States
    Document type Journal Article
    ZDB-ID 2084287-9
    ISSN 1520-4383 ; 1520-4391
    ISSN (online) 1520-4383
    ISSN 1520-4391
    DOI 10.1182/hematology.2023000445
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

    Order via subito

    This service is chargeable due to the Delivery terms set by subito. Orders including an article and supplementary material will be classified as separate orders. In these cases, fees will be demanded for each order.

  4. Article ; Online: Ultra-clean pure shift NMR with optimal water suppression for analysis of aqueous pharmaceutical samples.

    Dal Poggetto, Guilherme / DiCaprio, Adam / Reibarkh, Mikhail / Cohen, Ryan D

    The Analyst

    2024  Volume 149, Issue 8, Page(s) 2227–2231

    Abstract: Pure shift NMR experiments greatly enhance spectral resolution by collapsing multiplet structures into singlets and, with water suppression, can be used for aqueous samples. Here, we combine ultra-clean pure-shift NMR (SAPPHIRE) with two different ... ...

    Abstract Pure shift NMR experiments greatly enhance spectral resolution by collapsing multiplet structures into singlets and, with water suppression, can be used for aqueous samples. Here, we combine ultra-clean pure-shift NMR (SAPPHIRE) with two different internally encoded water suppression schemes to achieve optimal performance for small molecule and macrocyclic peptide pharmaceuticals in water and acetonitrile-water mixtures.
    MeSH term(s) Water ; Magnetic Resonance Spectroscopy ; Magnetic Resonance Imaging ; Pharmaceutical Preparations
    Chemical Substances Water (059QF0KO0R) ; Pharmaceutical Preparations
    Language English
    Publishing date 2024-04-15
    Publishing country England
    Document type Journal Article
    ZDB-ID 210747-8
    ISSN 1364-5528 ; 0003-2654
    ISSN (online) 1364-5528
    ISSN 0003-2654
    DOI 10.1039/d3an02150e
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

    In stock of ZB MED Cologne/Königswinter

    Zs.A 2423: Show issues Location:
    Je nach Verfügbarkeit (siehe Angabe bei Bestand)
    bis Jg. 1994: Bestellungen von Artikeln über das Online-Bestellformular
    Jg. 1995 - 2021: Lesesall (2.OG)
    ab Jg. 2022: Lesesaal (EG)

    Order via subito

    This service is chargeable due to the Delivery terms set by subito. Orders including an article and supplementary material will be classified as separate orders. In these cases, fees will be demanded for each order.

  5. Article ; Online: CAR T cell therapy for multiple myeloma: What have we learned?

    Susanibar Adaniya, Sandra / Stadtmauer, Edward A / Cohen, Adam D

    Leukemia

    2022  Volume 36, Issue 6, Page(s) 1481–1484

    MeSH term(s) B-Cell Maturation Antigen ; Humans ; Immunotherapy, Adoptive ; Multiple Myeloma/therapy ; Receptors, Chimeric Antigen
    Chemical Substances B-Cell Maturation Antigen ; Receptors, Chimeric Antigen
    Language English
    Publishing date 2022-03-29
    Publishing country England
    Document type Journal Article ; Review
    ZDB-ID 807030-1
    ISSN 1476-5551 ; 0887-6924
    ISSN (online) 1476-5551
    ISSN 0887-6924
    DOI 10.1038/s41375-022-01539-8
    Database MEDical Literature Analysis and Retrieval System OnLINE

    Full text online

    More links

    Kategorien

    In stock of ZB MED Cologne/Königswinter

    Zs.A 2295: Show issues Location:
    Je nach Verfügbarkeit (siehe Angabe bei Bestand)
    bis Jg. 1994: Bestellungen von Artikeln über das Online-Bestellformular
    Jg. 1995 - 2021: Lesesall (2.OG)
    ab Jg. 2022: Lesesaal (EG)

    Order via subito

    This service is chargeable due to the Delivery terms set by subito. Orders including an article and supplementary material will be classified as separate orders. In these cases, fees will be demanded for each order.

  6. Article ; Online: CAR T Cells and Other Cellular Therapies for Multiple Myeloma: 2018 Update.

    Cohen, Adam D

    American Society of Clinical Oncology educational book. American Society of Clinical Oncology. Annual Meeting

    2018  Volume 38, Page(s) e6–e15

    Abstract: Cellular therapies are a rapidly evolving approach to myeloma treatment, which bring a unique mechanism of action with the potential to overcome drug resistance and induce long-term remissions. Two primary approaches are being studied: non-gene-modified ... ...

    Abstract Cellular therapies are a rapidly evolving approach to myeloma treatment, which bring a unique mechanism of action with the potential to overcome drug resistance and induce long-term remissions. Two primary approaches are being studied: non-gene-modified strategies, which rely on the endogenous anti-myeloma T-cell repertoire, and gene-modified strategies, which introduce a new T-cell receptor (TCR) or a chimeric antigen receptor (CAR) to confer novel antigen specificity. CAR T cells show the greatest activity to date. Multiple antigen targets, including B-cell maturation antigen (BCMA), CD19, CD38, CD138, and SLAMF7, are being explored for myeloma, and BCMA has emerged as the most promising. Preliminary data from four phase I studies of BCMA CAR T cells, each using a different CAR construct, that involved 90 evaluable patients with relapsed/refractory disease have been reported. These data show response rates of 60% to 100%, including minimal residual disease (MRD)-negative complete remissions, at effective doses (> 10
    MeSH term(s) Antigens, Neoplasm/immunology ; Cell- and Tissue-Based Therapy/methods ; Gene Transfer Techniques ; Genetic Therapy/methods ; Humans ; Immunotherapy, Adoptive/adverse effects ; Immunotherapy, Adoptive/methods ; Multiple Myeloma/genetics ; Multiple Myeloma/immunology ; Multiple Myeloma/metabolism ; Multiple Myeloma/therapy ; Receptors, Antigen, T-Cell/genetics ; Receptors, Antigen, T-Cell/metabolism ; Recombinant Fusion Proteins ; T-Lymphocytes/immunology ; T-Lymphocytes/metabolism ; Transduction, Genetic
    Chemical Substances Antigens, Neoplasm ; Receptors, Antigen, T-Cell ; Recombinant Fusion Proteins
    Language English
    Publishing date 2018-09-19
    Publishing country United States
    Document type Journal Article ; Review
    ISSN 1548-8756 ; 1092-9118 ; 1548-8748
    ISSN (online) 1548-8756
    ISSN 1092-9118 ; 1548-8748
    DOI 10.1200/EDBK_200889
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

    Order via subito

    This service is chargeable due to the Delivery terms set by subito. Orders including an article and supplementary material will be classified as separate orders. In these cases, fees will be demanded for each order.

  7. Article ; Online: Practical Aspects of Immunotherapy: A Report from the 20th International Myeloma Society (IMS) Annual Meeting.

    Raje, Noopur S / Cohen, Adam D / Patel, Krina K / van de Donk, Niels W C J / Richter, Joshua / San-Miguel, Jesus

    Clinical lymphoma, myeloma & leukemia

    2024  

    Abstract: Immunotherapeutic strategies, specifically T-cell-redirected therapies, have been transformative in the context of multiple myeloma (MM). With the approval of two chimeric antigen receptor T-cell (CAR-T) drug products and three bispecific antibodies/T- ... ...

    Abstract Immunotherapeutic strategies, specifically T-cell-redirected therapies, have been transformative in the context of multiple myeloma (MM). With the approval of two chimeric antigen receptor T-cell (CAR-T) drug products and three bispecific antibodies/T-cell engagers (bsAbs/TCEs) in relapsed/refractory MM (RRMM), the 20th annual IMS meeting dedicated a session to the practical aspects of these therapies. Here, we highlight the discussion during this session, including the role of CAR-T and bsAb therapies in frontline MM treatment, management of acute toxicities, prevention and management of infections, and finally treatment sequencing of T-cell redirected therapies.
    Language English
    Publishing date 2024-03-22
    Publishing country United States
    Document type Journal Article
    ZDB-ID 2540992-X
    ISSN 2152-2669 ; 2152-2650
    ISSN (online) 2152-2669
    ISSN 2152-2650
    DOI 10.1016/j.clml.2024.03.005
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

    In stock of ZB MED Cologne/Königswinter

    Zs.A 5903: Show issues Location:
    Je nach Verfügbarkeit (siehe Angabe bei Bestand)
    bis Jg. 1994: Bestellungen von Artikeln über das Online-Bestellformular
    Jg. 1995 - 2021: Lesesall (2.OG)
    ab Jg. 2022: Lesesaal (EG)

    Order via subito

    This service is chargeable due to the Delivery terms set by subito. Orders including an article and supplementary material will be classified as separate orders. In these cases, fees will be demanded for each order.

  8. Article ; Online: Specific connectivity optimizes learning in thalamocortical loops.

    Lakshminarasimhan, Kaushik J / Xie, Marjorie / Cohen, Jeremy D / Sauerbrei, Britton A / Hantman, Adam W / Litwin-Kumar, Ashok / Escola, Sean

    Cell reports

    2024  Volume 43, Issue 4, Page(s) 114059

    Abstract: Thalamocortical loops have a central role in cognition and motor control, but precisely how they contribute to these processes is unclear. Recent studies showing evidence of plasticity in thalamocortical synapses indicate a role for the thalamus in ... ...

    Abstract Thalamocortical loops have a central role in cognition and motor control, but precisely how they contribute to these processes is unclear. Recent studies showing evidence of plasticity in thalamocortical synapses indicate a role for the thalamus in shaping cortical dynamics through learning. Since signals undergo a compression from the cortex to the thalamus, we hypothesized that the computational role of the thalamus depends critically on the structure of corticothalamic connectivity. To test this, we identified the optimal corticothalamic structure that promotes biologically plausible learning in thalamocortical synapses. We found that corticothalamic projections specialized to communicate an efference copy of the cortical output benefit motor control, while communicating the modes of highest variance is optimal for working memory tasks. We analyzed neural recordings from mice performing grasping and delayed discrimination tasks and found corticothalamic communication consistent with these predictions. These results suggest that the thalamus orchestrates cortical dynamics in a functionally precise manner through structured connectivity.
    MeSH term(s) Thalamus/physiology ; Animals ; Mice ; Learning/physiology ; Cerebral Cortex/physiology ; Memory, Short-Term/physiology ; Neural Pathways/physiology ; Synapses/physiology ; Mice, Inbred C57BL ; Male
    Language English
    Publishing date 2024-04-10
    Publishing country United States
    Document type Journal Article ; Research Support, Non-U.S. Gov't ; Research Support, N.I.H., Extramural
    ZDB-ID 2649101-1
    ISSN 2211-1247 ; 2211-1247
    ISSN (online) 2211-1247
    ISSN 2211-1247
    DOI 10.1016/j.celrep.2024.114059
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

    Order via subito

    This service is chargeable due to the Delivery terms set by subito. Orders including an article and supplementary material will be classified as separate orders. In these cases, fees will be demanded for each order.

  9. Article ; Online: H3 K27-altered diffuse midline glioma presenting as massive cerebellopontine hemorrhage.

    Azad, Tej D / Kalluri, Anita L / Hansen, Landon J / Ammar, Adam / Cohen, Alan R

    Child's nervous system : ChNS : official journal of the International Society for Pediatric Neurosurgery

    2023  Volume 39, Issue 8, Page(s) 2229–2232

    Abstract: We report the case of a 14-year-old boy who presented with extensive cerebellar and brainstem hemorrhage. Our presumptive diagnosis was a ruptured arteriovenous malformation (AVM), but two cerebral angiograms showed no significant vascular abnormalities. ...

    Abstract We report the case of a 14-year-old boy who presented with extensive cerebellar and brainstem hemorrhage. Our presumptive diagnosis was a ruptured arteriovenous malformation (AVM), but two cerebral angiograms showed no significant vascular abnormalities. The patient underwent posterior fossa craniotomy and microsurgical evacuation of the hematoma. Pathological analysis of the hemorrhagic tissue made the diagnosis of diffuse midline glioma, H3 K27-altered (WHO grade 4), based on immunohistochemistry. He subsequently developed diffuse craniospinal leptomeningeal disease and progressed rapidly, with respiratory failure followed by severe neurologic decline without further hemorrhage. He was compassionately extubated at the request of the family and died before initiation of adjuvant therapy. This unusual case of a diffuse midline glioma presenting with massive hemorrhage underscores the importance of searching for an underlying etiology of hemorrhage in a child when a vascular lesion cannot be identified.
    MeSH term(s) Male ; Child ; Humans ; Adolescent ; Glioma/complications ; Glioma/diagnostic imaging ; Glioma/pathology ; Cerebellum ; Hematoma ; Cerebral Hemorrhage/diagnostic imaging ; Cerebral Hemorrhage/etiology ; Cerebral Hemorrhage/surgery ; Mutation
    Language English
    Publishing date 2023-03-03
    Publishing country Germany
    Document type Case Reports ; Journal Article
    ZDB-ID 605988-0
    ISSN 1433-0350 ; 0302-2803 ; 0256-7040
    ISSN (online) 1433-0350
    ISSN 0302-2803 ; 0256-7040
    DOI 10.1007/s00381-023-05904-5
    Database MEDical Literature Analysis and Retrieval System OnLINE

    Full text online

    More links

    Kategorien

    In stock of ZB MED Cologne/Königswinter

    Zs.A 2036: Show issues Location:
    Je nach Verfügbarkeit (siehe Angabe bei Bestand)
    bis Jg. 1994: Bestellungen von Artikeln über das Online-Bestellformular
    Jg. 1995 - 2021: Lesesall (1.OG)
    ab Jg. 2022: Lesesaal (EG)

    Order via subito

    This service is chargeable due to the Delivery terms set by subito. Orders including an article and supplementary material will be classified as separate orders. In these cases, fees will be demanded for each order.

  10. Article: Systematic Review of WHO Grade 4 Astrocytoma in the Cerebellopontine Angle: The Impact of Anatomic Corridor on Treatment Options and Outcomes.

    Dang, Danielle D / Gong, Andrew D / Dang, John V / Mugge, Luke A / Mansinghani, Seth / Ziu, Mateo / Cohen, Adam L / Vyas, Nilesh

    Journal of neurological surgery reports

    2023  Volume 84, Issue 4, Page(s) e129–e139

    Abstract: ... ...

    Abstract Background
    Language English
    Publishing date 2023-10-16
    Publishing country Germany
    Document type Journal Article
    ZDB-ID 2653397-2
    ISSN 2193-6366 ; 2193-6358
    ISSN (online) 2193-6366
    ISSN 2193-6358
    DOI 10.1055/a-2172-7770
    Database MEDical Literature Analysis and Retrieval System OnLINE

    Full text online

    More links

    Kategorien

    In stock of ZB MED Cologne/Königswinter

    Zs.A 6973: Show issues Location:
    Je nach Verfügbarkeit (siehe Angabe bei Bestand)
    bis Jg. 2021: Bestellungen von Artikeln über das Online-Bestellformular
    ab Jg. 2022: Lesesaal (EG)

    Order via subito

    This service is chargeable due to the Delivery terms set by subito. Orders including an article and supplementary material will be classified as separate orders. In these cases, fees will be demanded for each order.

To top